Equisolon
Active substance
ATC code
Species
Horses.
Indications
Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO) in horses, in combination with environmental control.
Dose to be administered and administration route
Oral use.
To ensure administration of the correct dose, body weight should be determined as accurately as possible to avoid under- or overdosing.
A single dose of 1 mg prednisolone/kg body weight per day corresponds to 3 g powder per 100 kg body weight (see dosing table below).
Treatment may be repeated at 24 hour intervals during 10 consecutive days.
The correct dose should be mixed into a small amount of food.
Food mixed with the veterinary medicinal product should be replaced if not consumed within 24 hours.
Using the measuring spoon the following dosing table applies:
Bodyweight (kg) of horse | Jar with measuring spoon (1 spoon = 4.6 g powder) |
Number of spoons | |
150-300 | 2 |
300-450 | 3 |
450-600 | 4 |
600-750 | 6 |
750-1000 | 7 |
Adverse reactions
Very rarely, laminitis has been observed after use of the product. Therefore horses should be monitored frequently during the treatment period.
Very rarely, neurological signs such as ataxia, recumbency, head tilting, restlessness or incoordination have been observed after use of the product.
Whilst single high doses of corticosteroids are generally well tolerated, they may induce severe sideeffects in long term use. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control symptoms.
The significant dose related cortisol suppression very commonly noticed during therapy is a result of effective doses suppressing the hypothalamo-pituitreal adrenal axis.
Following cessation of treatment, signs of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations.
A significant increase in triglycerids occurs very commonly. This can be a part of possible iatrogenic hyperadrenocorticism (Cushings disease) involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, increase in body weight, muscle weakness and wastage and osteoporosis may result.
An increase of alkaline phosphatase by glucocorticoids is very rarely observed and could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Gastrointestinal ulceration has been very rarely reported and gastrointestinal ulceration may be exacerbated by steroids in animals given non-steroidal anti-inflammatory drugs and in animals with spinal cord trauma (see section 4.3). Other gastrointestinal symptoms that have been very rarely observed are colic and anorexia.
Excessive sweating has been very rarely observed. Very rarely urticaria has been observed.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | |
| EAN | 5701170444889 |
